It was unexpected to find significant differences in VGLL4 when comparing Q2 and Q3 expression levels across standard and low risk subgroups in the paediatric AML patients, especially because significant differences in VGLL4 transcription were not found between Q1 and Q4 levels. This evidence concerns the gene VGLL4 and acute myeloid leukemia.